Sign inJoin waitlistJoin the waitlist

Eunice Wang

, SUNY Distinguished Professor of Medicine and Chief of · University at Buffalo School of Medicine

Credentials: · · ·

History

medicine and chief of Division · University at Buffalo School of Medicine
Present
Academic Affairs · ROSWELL PARK CANCER INSTITUTE
Present
University at Buffalo School of Medicine
Present

Memorial Sloan Kettering Cancer Center
2002–2003
Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
1999–2002
Yale-New Haven Hospital
1996–1999
Keck Sch of Med of the Univ of Southern Calif
1992–1996
Pathology-Anatomic and Clinical
Harvard University
1987–1991

Research

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
The Lancet Oncology · 2017 · 424 citations
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Cancer Discovery · 2019 · 371 citations
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2019 · 359 citations

MW
Meir Wetzler
59 papers
Elizabeth Griffiths
44 papers
Richard Stone
37 papers
James Thompson
26 papers
JK
Jonathan Kolitz
22 papers
Bayard Powell
19 papers
CB
Clara Bloomfield
19 papers
Hagop Kantarjian
17 papers
Maria Baer
17 papers
Jessica Altman
16 papers
Alexander Perl
15 papers
Amanda Przespolewski
15 papers · 2 as a fellow

Clinical trials

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Principal investigator · Completed · Phase 2
Roswell Park Cancer Institute
2021–2026
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Principal investigator · Withdrawn · Phase 1, Phase 2
Roswell Park Cancer Institute
2021–2024
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1
Roswell Park Cancer Institute
2020–2024
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Principal investigator · Completed · Phase 3
Arog Pharmaceuticals, Inc.
2018–2026